To expand its portfolio of drugs that target autoimmune diseases, Merck & Co is buying drug developer Pandion Therapeutics for around US$1.85bn in cash. The US$60-per-share deal represents about 134%…
Merck to buy drug developer
Would you like to read this article?
Register below to continue reading this article.
You will be able to read 2 articles. No payment details required.
You will also receive our daily M&A insights email.
There is no obligation to subscribe to the service but we hope that after the trialing your firm will decide to subscribe.
For details of subscription packages or if you are considering a subscription and would like to read a few more articles on your trial, please contact us at firstname.lastname@example.org and we will call you to discuss.
Already a subscriber? Login here